These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

112 related items for PubMed ID: 20534288

  • 1. Conversion of stable kidney transplant recipients from a twice-daily to once-daily everolimus regimen.
    Carmellini M, Collini A, Ruggieri G, Bernini M.
    Transplant Proc; 2010 May; 42(4):1312-3. PubMed ID: 20534288
    [Abstract] [Full Text] [Related]

  • 2. Renal function outcomes in kidney transplant recipients after conversion to everolimus-based immunosuppression regimen with CNI reduction or elimination.
    Cataneo-Dávila A, Zúñiga-Varga J, Correa-Rotter R, Alberú J.
    Transplant Proc; 2009 Dec; 41(10):4138-46. PubMed ID: 20005355
    [Abstract] [Full Text] [Related]

  • 3. Everolimus and reduced cyclosporine trough levels in maintenance heart transplant recipients.
    Schweiger M, Wasler A, Prenner G, Stiegler P, Stadlbauer V, Schwarz M, Tscheliessnigg K.
    Transpl Immunol; 2006 Jun; 16(1):46-51. PubMed ID: 16701176
    [Abstract] [Full Text] [Related]

  • 4. Everolimus with very low-exposure cyclosporine a in de novo kidney transplantation: a multicenter, randomized, controlled trial.
    Salvadori M, Scolari MP, Bertoni E, Citterio F, Rigotti P, Cossu M, Dal Canton A, Tisone G, Albertazzi A, Pisani F, Gubbiotti G, Piredda G, Busnach G, Sparacino V, Goepel V, Messa P, Berloco P, Montanaro D, Veroux P, Federico S, Bartezaghi M, Corbetta G, Ponticelli C.
    Transplantation; 2009 Nov 27; 88(10):1194-202. PubMed ID: 19935373
    [Abstract] [Full Text] [Related]

  • 5. A randomized trial of steroid avoidance in renal transplant patients treated with everolimus and cyclosporine.
    Montagnino G, Sandrini S, Casciani C, Schena FP, Carmellini M, Civati G, Rigotti P, Cossu M, Altieri P, Salvadori M, Federico S, Stefoni S, Cambi V, Albertazzi A, Buoncristiani U, Berloco P, Segoloni G, Boschiero L, Sparacino V, Donati D, Turello E, Dal Canton A, Ponticelli C.
    Transplant Proc; 2005 Mar 27; 37(2):788-90. PubMed ID: 15848532
    [Abstract] [Full Text] [Related]

  • 6. Once-a-day administration of everolimus, cyclosporine, and steroid after renal transplantation: a review of the rationale.
    Corbetta G, Ponticelli C.
    Transplant Proc; 2010 May 27; 42(4):1303-7. PubMed ID: 20534286
    [Abstract] [Full Text] [Related]

  • 7. Long-term results of kidney transplantation with cyclosporine- and everolimus-based immunosuppression.
    Iaria G, Pisani F, Iorio B, Lucchesi C, De Luca L, Ielpo B, D'Andria D, Tariciotti L, Tisone G.
    Transplant Proc; 2006 May 27; 38(4):1018-9. PubMed ID: 16757249
    [Abstract] [Full Text] [Related]

  • 8. Everolimus versus azathioprine in a cyclosporine and ketoconazole-based immunosuppressive therapy in kidney transplant: 3-year follow-up of an open-label, prospective, cohort, comparative clinical trial.
    Gonzalez F, Espinoza M, Herrera P, Rocca X, Reynolds E, Lorca E, Roessler E, Hidalgo J, Espinoza O.
    Transplant Proc; 2010 May 27; 42(1):270-2. PubMed ID: 20172327
    [Abstract] [Full Text] [Related]

  • 9. Conversion to everolimus in maintenance patients--current clinical strategies.
    Pohanka E.
    Nephrol Dial Transplant; 2006 Jul 27; 21 Suppl 3():iii24-9. PubMed ID: 16815853
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Late acute cardiac allograft rejection: new therapeutic options?
    Schweiger M, Wasler A, Prenner G, Tripolt M, Schwarz M, Tscheliessnigg KH.
    Transplant Proc; 2005 Dec 27; 37(10):4528-31. PubMed ID: 16387161
    [Abstract] [Full Text] [Related]

  • 13. Cyclosporine reduction in the presence of everolimus: 3-month data from a Canadian pilot study of maintenance cardiac allograft recipients.
    Ross H, Pflugfelder P, Haddad H, Cantarovich M, White M, Ignaszewski A, Howlett J, Vaillancourt M, Dorent R, Burton JR, CADENCE Study Group.
    J Heart Lung Transplant; 2008 Feb 27; 27(2):197-202. PubMed ID: 18267227
    [Abstract] [Full Text] [Related]

  • 14. Once daily everolimus is safe and effective in de novo renal transplant recipients: six-month results of a pilot study.
    Favi E, Spagnoletti G, Gargiulo A, Salerno MP, Romagnoli J, Citterio F.
    Transplant Proc; 2010 May 27; 42(4):1308-11. PubMed ID: 20534287
    [Abstract] [Full Text] [Related]

  • 15. Can cyclosporine blood level be reduced to half after heart transplantation?
    Wang SS, Chou NK, Chi NH, Huang SC, Wu IH, Wang CH, Yu HY, Chen YS, Tsao CI, Ko WJ, Shun CT.
    Transplant Proc; 2010 Apr 27; 42(3):930-3. PubMed ID: 20430207
    [Abstract] [Full Text] [Related]

  • 16. Early sirolimus therapy in renal transplant recipients at high risk: is it justified?
    Halim MA, Al-Otaibi T, Johny KV, Hamid MH, Al-Waheeb S, Hasaneen H, Awadain WH, Nawas KM, El-Sayed A, Said T, Nair MP, Nampoory MR.
    Transplant Proc; 2009 Sep 27; 41(7):2784-8. PubMed ID: 19765435
    [Abstract] [Full Text] [Related]

  • 17. Single daily dose administration of cyclosporine in renal transplant recipients.
    Halim MA, Said T, Al-Otaibi T, Eleawa S, Al-Maged H, Gawish AE, Nair P, Al-Muzairai I, Nampoory MR, Al-Mousawi M.
    Transplant Proc; 2007 May 27; 39(4):1225-7. PubMed ID: 17524939
    [Abstract] [Full Text] [Related]

  • 18. A phase III prospective, randomized study to evaluate concentration-controlled sirolimus (rapamune) with cyclosporine dose minimization or elimination at six months in de novo renal allograft recipients.
    Baboolal K.
    Transplantation; 2003 Apr 27; 75(8):1404-8. PubMed ID: 12717239
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.